#AS­CO21: Nanobi­otix says ear­ly da­ta show 'very strong' sig­nal that its nanopar­ti­cles can di­al up an­ti­tu­mor re­sponse

While can­cer im­munother­a­pies have shown promise, Nanobi­otix thinks it can use nanopar­ti­cles to di­al up the tu­mor killing ef­fect of ra­di­a­tion and check­point in­hibitors. And just ahead of #AS­CO21, the com­pa­ny said about 77% of pa­tients who used the tech in a small Phase I tri­al saw their tu­mors shrink.

NBTXR3 con­sists of crys­talline nanopar­ti­cles that are de­liv­ered by in­tra­tu­moral in­jec­tions. When ac­ti­vat­ed by ra­di­a­tion, the nanopar­ti­cles ab­sorb en­er­gy and de­liv­er a “high quan­ti­ty of dam­age,” CEO Lau­rent Levy told End­points News. It’s al­so de­signed to trig­ger an adap­tive im­mune re­sponse and long-term an­ti-can­cer mem­o­ry.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.